beta(2)-Microglobulin-selective direct hemoperfusion column for the treatment of dialysis-related amyloidosis.
Lixelle is a direct hemoperfusion-type adsorption column that was developed to selectively eliminate beta2-microglobulin (beta2-m) from the circulating blood of patients with dialysis-related amyloidosis (DRA). The adsorbent in Lixelle comprises porous cellulose beads to which hydrophobic hexadecyl alkyl chain is covalently bound. One milliliter of wet Lixelle beads eliminates more than 1 mg of beta2-m in vitro. In hemodialysis patients who were treated with Lixelle, Lixelle improved joint pain, nocturnal awakening, pinch strength, motor terminal latency, and their activity of daily living. The adsorbent adsorbs beta2-m selectively but not specifically, as well as inflammatory cytokines such as interleukin-1beta and IL-6 which are considered to be involved in the development of DRA. Lixelle treatments reduce the circulating levels of beta2-m and inflammatory cytokines, thereby improving the symptoms of patients with DRA.
Kutsuki
Hidetoshi
H
Medical Devices Division, Kaneka Corporation, 3-2-4 Nakanoshima, Kita-ku, 530-8288 Osaka, Osaka, Japan. hidetoshi_kutsuki@kn.kaneka.co.jp
D000327:Adsorption; D000686:Amyloidosis / Q000209:etiology / Q000628:therapy*; D001672:Biocompatible Materials; D002482:Cellulose; D002986:Clinical Trials as Topic; D006464:Hemoperfusion / Q000379:methods*; D006801:Humans; D007375:Interleukin-1 / Q000302:isolation & purification; D015850:Interleukin-6 / Q000302:isolation & purification; D006435:Renal Dialysis / Q000009:adverse effects
D001672:Biocompatible Materials; D007375:Interleukin-1; D015850:Interleukin-6; D002482:Cellulose